This section contains information on the COVID-19 antiviral treatment Paxlovid™ (PF-07321332 + ritonavir).

The documents below include correspondence from the HSE-MMP providing an update on Paxlovid™ (PF-07321332 + ritonavir) and highlighting prescribing issues (particularly drug-drug interactions) associated with this medicine.

Due to the risk of drug-drug interactions a full review of patient medication history and interaction risk is required prior to initiating a prescription for Paxlovid™ (PF-07321332 + ritonavir). Refer to the Summary of Product Characteristics and other suitable reference sources (see correspondence below) to review possible medicines that may interact with Paxlovid™ (PF-07321332 + ritonavir).

The National Medicines Information Centre (NMIC) is available to assist prescribers with drug-drug interaction enquiries specific to the prescribing of Paxlovid™ (PF-07321332 + ritonavir) through their enquiry answering service. This service can be accessed via a secure email (e.g. Healthmail) at using the template provided below.

For further information on COVID-19 treatments, including Paxlovid™ (PF-07321332 + ritonavir), please consult the HSE Interim Guidance for the Pharmacological Management of Patients with COVID-19 v4.1.